IL33 and brain injury: Liu et al. found that the administration of exosomes derived from BMSCs into a mouse model of ischemic brain injury reduced the volume of cerebral infarction, increased the level of Interleukin-33 (IL-33), inhibited tumorigenicity 2 (ST2), and improved neurological function (Liu et al., 2023).